Journal Logo


Crowds ASPIRE to Hear Myeloma Report

Carlson, Robert H.

doi: 10.1097/
  • Free

SAN FRANCISCO—The session on “Myeloma Therapy, Excluding Transplantation” here at the American Society of Hematology Annual Meeting was so popular that one of the largest halls in the Moscone Convention Center immediately filled to capacity as soon as the doors opened. An “overflow room” was designated, but that too filled up fast, so the crowd in the hallway was directed to a second overflow room on the next floor. Then that room filled up as well, leaving about 200 attendees standing in the hallway watching the proceedings on a large television screen.

What attendees heard first was the much anticipated interim results from the ASPIRE trial, a randomized, open-label Phase III trial of KRd (carfilzomib [Kyprolis]-lenalidomide [Revlimid]-low dose dexamethasone) versus Rd (lenalidomide-low dose dexamethasone) in patients with relapsed multiple myeloma following treatment with one to three prior regimens (Abstract 79).

A. Keith Stewart, MD, Dean for Research and Professor of Cancer Research at the Mayo Clinic in Arizona, presented the data on 792 patients in the U.S., Europe, and Israel. The trial was sponsored by the maker of carfilzomib, Onyx, an Amgen subsidiary.

Stewart reported that the primary endpoint, progression-free survival, favored the three-drug combination: median progression-free survival was 26.3 months versus 17.6 months for the two-drug arm.

“Progression-free survival of over two years is unprecedented in myeloma,” Stewart said.

Overall response was also impressive for carfilzomib-lenalidomide-dexamethasone: The mean time to response was 1.6 months for KRd versus 2.3 months for Rd.

The rate of complete response was 31.8 percent for KRd—three times the 9.3 percent for Rd. And the rate of very good partial response was 69.9 percent for KRd versus 40.4 percent for Rd. Median duration of response was 28.6 vs. 21.2 months, respectively.

Stewart said at this time the median overall survival has not been met, although there is a trend toward superiority for the triplet combination.

Adverse Events Manageable

Adverse events were manageable, he said. “Despite adding a third drug to the cocktail treatment the patients were taking, adverse events were virtually the same for both study arms,” Stewart noted.

A. KEITH STEWART, MD. A. KEITH STEWART, MD: “Progression-free survival of over two years is unprecedented in myeloma.”

He said cardiac and renal events were reported at rates consistent with or lower than prior studies of single-agent carfilzomib.

At a news conference earlier in the meeting, Stewart was asked about peripheral neuropathy, a concern with bortezomib. He said there was no increase in peripheral neuropathy with the triplet combination containing carfilzomib, confirming that carfilzomib does not cause that side effect.

Stewart said there had been speculation about cardiac toxicity with carfilzomib, but what was seen in ASPIRE was only an increase in hypertension—14 percent for KRd versus eight percent for Rd.

“KRd should be the standard of care for relapsed myeloma as of today,” Stewart said.

‘New Standard’

“Dr. Steward's study will establish a new standard of care in multiple myeloma,” agreed the moderator of the news conference, Brad S. Kahl, MD, Associate Professor of Medicine at the University of Wisconsin and Director of the UW Lymphoma Service and Clinical Research Director for Hematologic Malignancies at the University of Wisconsin Carbone Cancer Center.

‘One of the Easier Drugs’

Asked for his opinion for this article, Saad Usmani, MD, Director of Clinical Research in Hematologic Malignancies and Head of the Myeloma Program at Levine Cancer Institute in Charlotte, N.C., said one consideration when using two versus three drugs in a heavily pretreated population is whether toxicity will increase. “What we see with this combination, however, is that the toxicity profile is really good, very comparable to lenalidomide-dexamethasone,” he said.

Usmani also noted that in the past there have been concerns about unusual cardiac toxicities with carfilzomib, but these were not reported in significant numbers in ASPIRE, Usmani noted. “They were slightly increased in the carfilzomib arm, but in the three to four percent range compared with one-and-a-half percent on the standard arm.”

He said he has used carfilzomib to treat many patients on clinical trials, “and I think it's one of the easier drugs in myeloma therapy today.

“Clinical practice will be impacted by the ASPIRE study,” Usmani said. “When patients are potentially eligible for lenalidomide and dexamethasone treatment, physicians would be thinking that it wouldn't add a lot of toxicity to add carfilzomib and they could give their patients almost a year of additional progression-free survival.”

© 2015 by Lippincott Williams & Wilkins, Inc.
    Home  Clinical Resource Center
    Current Issue       Search OT
    Archives Get OT Enews
    Blogs Email us!